Disitamab Vedotin vs Trastuzumab rezetecan
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: HER2 · full Non-Small Cell Lung Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT04311034 · Phase 1/2 · completed
The study was an uncontrolled, open-label single-arm trial of 37 participants, so it could not compare disitamab vedotin with placebo or another treatment. Its primary outcomes were clinical tumor measures, but the primary endpoint result has not been reported.
Next expected readout: June 2027 · NCT06734182 (registry estimate)
No aligned efficacy figure on record for this race.
Trastuzumab rezetecan
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05482568 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Disitamab Vedotin | Trastuzumab rezetecan |
|---|---|---|
| PFS, median | —Not reported | —Trial running · NCT06430437 |
| OS, median | —Not reported | —Trial running · NCT06430437 |
| ORR | —Not reported | —Trial running · NCT06430437 |
| Duration of response, median | —Not reported | —Trial running · NCT06430437 |
PFS, median
- Disitamab Vedotin
- —Not reported
- Trastuzumab rezetecan
- —Trial running · NCT06430437
OS, median
- Disitamab Vedotin
- —Not reported
- Trastuzumab rezetecan
- —Trial running · NCT06430437
ORR
- Disitamab Vedotin
- —Not reported
- Trastuzumab rezetecan
- —Trial running · NCT06430437
Duration of response, median
- Disitamab Vedotin
- —Not reported
- Trastuzumab rezetecan
- —Trial running · NCT06430437
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Disitamab Vedotin: no structured comparison results are available for Non-Small Cell Lung Cancer.
Trastuzumab rezetecan: no structured comparison results are available for Non-Small Cell Lung Cancer.
HER2-Positive Breast Cancer
Shared mechanism: HER2 · full HER2-Positive Breast Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT03500380 · Phase 2/3 · status unknown
This trial randomized 301 patients with HER2-positive metastatic breast cancer to disitamab vedotin or an active comparator regimen (lapatinib plus capecitabine), with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: January 2028 · NCT07366840 (registry estimate)
Reported efficacy
Progression-free Survival (PFS) as Assessed by an IRC (From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months): Median progression-free survival assessed by blinded independent review committee (phase 3 stage, 104 patients randomized): 9.9 months with disitamab vedotin versus 4.9 months with lapatinib plus capecitabine; stratified hazard ratio 0.56 (95.48% CI: 0.35-0.91). (met)
Result source: NCT03500380
Trastuzumab rezetecan
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT07416253 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HER2-Positive Breast Cancer
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Trastuzumab rezetecan: no structured comparison results are available for HER2-Positive Breast Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
HR+/HER2- Metastatic Breast Cancer
Shared mechanism: HER2 · full HR+/HER2- Metastatic Breast Cancer pipeline
Disitamab Vedotin
Marketed by RemeGen Co., Ltd. and partners
NCT04400695 · Phase 3 · recruiting
This trial randomized 366 patients with HER2-low breast cancer to disitamab vedotin or one of several standard chemotherapy options chosen by their physician, with tumor progression independently reviewed to reduce bias, but treatment assignment was not blinded. Results have not yet been posted to the registry.
Next expected readout: December 2026 · NCT05831878 (registry estimate)
Reported efficacy
RP2D (Estimated 2 year): Confirmed ORR at 2.0 mg/kg Q2W: 42.9% (9/21) in HER2-overexpression and 33.3% (22/66) in HER2-low advanced breast cancer; median PFS 5.7 and 5.1 months (not_applicable)
Result source: NCT03052634
Trastuzumab rezetecan
Marketed by Jiangsu Hengrui Pharmaceuticals and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: March 2027 · NCT06433609 (registry estimate)
No aligned efficacy figure on record for this race.
Results for HR+/HER2- Metastatic Breast Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Disitamab Vedotin | Trastuzumab rezetecan |
|---|---|---|
| PFS, median | —Trial running · NCT05904964 | —Trial running · NCT07382687 |
| OS, median | —Trial running · NCT05904964 | —Trial running · NCT07382687 |
| ORR | —Trial running · NCT05904964 | —Trial running · NCT07382687 |
| Clinical benefit rate | —Trial running · NCT05904964 | —Trial running · NCT07382687 |
PFS, median
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab rezetecan
- —Trial running · NCT07382687
OS, median
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab rezetecan
- —Trial running · NCT07382687
ORR
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab rezetecan
- —Trial running · NCT07382687
Clinical benefit rate
- Disitamab Vedotin
- —Trial running · NCT05904964
- Trastuzumab rezetecan
- —Trial running · NCT07382687
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Trastuzumab rezetecan: no structured comparison results are available for HR+/HER2- Metastatic Breast Cancer.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Disitamab Vedotin's landscape · Trastuzumab rezetecan's landscape